secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dare Bioscience, Inc. (DARE)
CIK:        0001401914
Form:       8-K
Filed at:   2025-12-01T23:59:59+00:00
Accession:  0001493152-25-025491
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bayer terminates Ovaprene license; Daré regains full rights, Phase 3 study continues
--------------------------------------------------------------------------------

- Bayer HealthCare terminated Ovaprene license agreement effective Feb 24, 2026 due to strategic prioritization.
- Daré regains full commercialization rights to Ovaprene, a hormone-free monthly intravaginal contraceptive.
- Pivotal Phase 3 study continues with positive interim data (July 2025) and Gates Foundation grant support.
- Enrollment expected to complete in 2026; no change to timelines or operations.
- Daré to explore partnerships and strategic transactions for Ovaprene.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401914/000149315225025491/0001493152-25-025491-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401914/000149315225025491/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-025491

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer